Study to Understand Clonal Hematopoiesis Effects in Adults Receiving Chemotherapy or Radiation for Solid Cancers

What this Trial Is About

Researchers are studying how clonal hematopoiesis CH affects people receiving chemotherapy and radiation for solid cancers. The goal is to understand clinical and molecular factors that predict high-risk CH in patients treated with cancer therapies. This research aims to identify cancer patients and survivors at increased risk for therapy-related myeloid neoplasms t-MNs, potentially leading to new ways to intercept progression to these serious conditions. Participants will provide tissue samples such as blood, buccal swabs, urine, stool, biopsy or surgical tissue, and other bodily fluids during routine visits or through remote collection at home. They will also complete intake surveys covering demographics, medical history, and family history. This observational study involves up to about 5,000 people diagnosed with solid malignancies who are planning to receive chemotherapy or radiation. During the study, participants samples and clinical data will be collected to analyze changes in CH and related outcomes over time, up to 5 to 10 years. Researchers will assess CH prevalence, gene distribution, variant changes, cancer progression, survival, hematologic toxicity, and development of therapy-related myeloid neoplasms. The study also aims to develop a predictive algorithm for adverse outcomes in patients with CH, with ongoing monitoring and data collection throughout the follow-up period.

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study